Because MYC deregulation in DLBCL is associated with aggressive clinical behaviour and poor outcomes, such as that seen in double-hit or double-expressor lymphomas,21,22 BET inhibition in these subtypes may be of particularly high therapeutic value, in addition to possible effects through disruption of other critical transcriptional pathways or modulation of microRNA expression.23 This evidence concerns the gene MYC and diffuse large B-cell lymphoma.